The Weekly Roundup: Cannabidiol Compounds (4.27.18)

April 27, 2018 | Pamela Youngberg Dickson

The times they are a-changin'. Compounds found in cannabis are rapidly gaining appreciation from the mainstream medical community. Last week, the FDA announced its support of a cannabidiol compound for its potential to treat seizure disorders. The treatment would be marketed under the name Epidiolex by UK-based GW Pharmaceuticals and, according to CEO Justin Gover, the approval of the drug “will mark a sea change in the acceptability of cannabinoids as therapy.” The deadline for approval is at the end of June, but many are speculating the unanimous support from the advisory panel indicates a slam-dunk for the drug maker.

Continue reading →